<DOC>
	<DOCNO>NCT02354612</DOCNO>
	<brief_summary>This multicenter , open-label , non-randomized , study TRC105 patient complete previous TRC105 study judge investigator potential benefit continue TRC105 therapy .</brief_summary>
	<brief_title>An Open Label Continuation Study TRC105 Therapy Patients Who Have Completed Prior TRC105 Trial Are Judged Investigator Have Potential Benefit From Continued TRC105 Therapy</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participation TRACON Pharmaceuticals sponsor parent TRC105 study , think potential derive clinical benefit continue treatment TRC105 opinion parent study investigator . Willing able consent self participate study Willing able comply schedule visit , treatment plan , laboratory test , study procedure . 18 year age old ability begin TRC105 dose protocol within 6 week subject last dose TRC105 parent TRC105 study Any clinical event would make TRC105 therapy inappropriate parent protocol Current treatment another clinical study Pregnant breastfeed Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>